Lead program potential STAR-LLD lenalidomide continuous delivery has the strongest near-term commercialization potential in multiple myeloma, with ongoing Phase 1b data and an expanding development plan that includes CLL, lymphoma, and solid tumors, presenting multiple upsell opportunities to oncology clinics.

Dermal delivery advantage Proprietary continuous low-dose dermal and alternative delivery platforms create routes to expand to subcutaneous, oral, transdermal, and on-body systems, enabling partnerships with contract development and manufacturing organizations and pharma companies seeking patient-friendly regimens.

Strategic partnerships Recent collaboration with Bend Bioscience for delivery R&D and manufacturing indicates a proven path to accelerate manufacturing readiness and scale, suggesting potential co-development or CRO/CMO partnerships to support STAR-LLD and future candidates.

Regulatory and funding Company pursuing a public listing and has secured modest funding, signaling readiness for larger capital raises and potential investor interest that can support late-stage trials, manufacturing scale, and broader market access collaborations.

Clinical momentum Positive Phase 1b data presentation at AACR and ongoing leadership updates imply growing clinical momentum, offering opportunities to engage oncology groups, patient advocacy channels, and payers early for favorable access and reimbursement discussions.